84. Sarcoidosis Clinical trials / Disease details


Clinical trials : 149 Drugs : 202 - (DrugBank : 78) / Drug target genes : 66 - Drug target pathways : 169

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-004794-31-NL
(EUCTR)
01/07/202210/05/2022A study to Assess the Efficacy and Safety of Namilumab in subjects with lung inflammatory diseaseA Randomized, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis - Resolve-Lung chronic pulmonary sarcoidosis
MedDRA version: 20.0;Level: PT;Classification code 10037430;Term: Pulmonary sarcoidosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Namilumab
Product Code: KIN-1902
INN or Proposed INN: NAMILUMAB
Kinevant Sciences GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 2France;United States;Belgium;Turkey;Germany;Netherlands;United Kingdom
2NCT05351554
(ClinicalTrials.gov)
June 30, 20224/4/2022A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac SarcoidosisA Randomized, Double-blind, Placebo-controlled, Phase 2a Study With an Open-label Cohort to Assess the Safety, Tolerability, and Efficacy of Namilumab in Subjects With Active Cardiac SarcoidosisSarcoidosis, CardiacDrug: Namilumab;Drug: Placebo;Drug: Open label NamilumabKinevant Sciences GmbHNULLTerminated18 YearsN/AAll1Phase 2United States
3NCT05314517
(ClinicalTrials.gov)
April 30, 202230/3/2022A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary SarcoidosisA Randomized, Double-blind, Placebo-Controlled Phase 2 Study With Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects With Chronic Pulmonary SarcoidosisSarcoidosis, PulmonaryDrug: Namilumab;Drug: PlaceboKinevant Sciences GmbHNULLRecruiting18 YearsN/AAll100Phase 2United States;Belgium;France;Netherlands